GLP-1 Pill
GLP-1 pill: three current FDA labels cover GLP-1 medicines that you swallow as a tablet.
Paste this code into your page. It shows the GLP-1 comparison chart with one plain credit link.
Learn
More about this page
They are Wegovy tablets, Rybelsus and Ozempic tablets, and Foundayo. Each label says to take the tablet once daily. The rest of the GLP-1 labels are shots.
The tablet labels side by side
| Tablet | Medicine | Maker | How often (label) | Approved uses (label) | Label version |
|---|---|---|---|---|---|
| Wegovy tablets | semaglutide | Novo Nordisk | Once daily Take one WEGOVY tablet orally once daily | Lower risk of major cardiovascular events Excess body weight, long term | v19, June 18, 2026 |
| Rybelsus and Ozempic tablets | semaglutide | Novo Nordisk | Once daily Take one RYBELSUS or OZEMPIC tablet orally once daily | Blood sugar in type 2 diabetes Lower risk of major cardiovascular events | v14, January 30, 2026 |
| Foundayo | orforglipron | Eli Lilly | Once daily Take FOUNDAYO orally once daily, with or without food. | Excess body weight, long term | v10, July 29, 2026 |
Wegovy tablets hold semaglutide. So do Rybelsus and Ozempic tablets, which share one label. That is the same medicine as in the Ozempic and Wegovy shots. Foundayo holds a different medicine, orforglipron. Its label calls it a GLP-1 receptor agonist.
Semaglutide tablets and shots have separate uses
Semaglutide comes as both a shot and a tablet. Its two tablet labels list their own uses.
- Wegovy tablets share one label with the Wegovy shot. The label gives the tablets a shorter list of uses than the shot. The MASH liver use is listed for the shot only.
- Rybelsus and Ozempic tablets share one label. That label is separate from the label for the Ozempic shot. The two labels list different uses.
The page on Ozempic vs Wegovy shows the shot labels line by line.
Foundayo, the newest label
Foundayo is the only tablet here that does not hold semaglutide. Its maker is Eli Lilly. Its label lists one use: to reduce excess body weight and keep it off long term. That is for adults with obesity, or adults with overweight and at least one weight-related health problem. The label pairs it with a reduced calorie diet and more physical activity.
The label prints "Initial U.S. Approval: 2026". The FDA approval record in Drugs@FDA is dated April 1, 2026. Back in 2018, a review noted that work was under way on GLP-1 medicines that could be taken by mouth.
Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.
How the tablet facts were checked
Each of the 115 label quotes on this site, including the ones in the tablet table, was matched word for word to the label files we saved from DailyMed on October 6, 2026. None differed.
To compare a tablet with any other label in the chart, open the GLP-1 comparison chart and pick up to 3. To see every brand by name, see the list of GLP-1 drugs.
Questions
Is there a GLP-1 pill?
Yes, there is a GLP-1 pill. Three current FDA labels cover GLP-1 tablets: Wegovy tablets, Rybelsus and Ozempic tablets, and Foundayo. Each label says to take the tablet once daily.
Is Rybelsus the same as Ozempic?
Rybelsus and Ozempic hold the same medicine, semaglutide. Rybelsus is a tablet, and Ozempic tablets share its label. The Ozempic shot has its own label, and the two labels list different uses.
What is the Wegovy pill?
The Wegovy pill is Wegovy in tablet form. It holds semaglutide and shares one label with the Wegovy shot. The label lists two uses for the tablets. One is to lower the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in adults with established cardiovascular disease and obesity or overweight. The other is excess body weight in adults.
What is Foundayo?
Foundayo is a once daily tablet that holds orforglipron, made by Eli Lilly. Its label calls it a GLP-1 receptor agonist. The FDA first approved it in 2026.
Sources
6 sources with read dates
- Wegovy label on DailyMed, Novo Nordisk, version 19 of 2026-06-18, read 2026-10-06
- Rybelsus and Ozempic tablets label on DailyMed, Novo Nordisk, version 14 of 2026-01-30, read 2026-10-06
- Foundayo label on DailyMed, Eli Lilly, version 10 of 2026-07-29, read 2026-10-06
- Ozempic label on DailyMed, Novo Nordisk, version 20 of 2026-06-01, read 2026-10-06
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
- Drugs@FDA: NDA 220934 (Foundayo), US Food and Drug Administration, via the openFDA drugsfda API, read 2026-10-06